Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ADNAN S PEER

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1962693150
CMS profile
89459
Location
HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$3,068.27

182 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,968.27 181
Consulting Fee $100.00 1

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 182 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ADNAN S PEER

NPI 1962693150 · CMS profile ID 89459

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 182 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1962693150?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ADNAN S PEER, NPI 1962693150, CMS profile ID 89459. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 182 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1962693150?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). ADNAN S PEER, NPI 1962693150, CMS profile ID 89459. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 182 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1962693150?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
ADNAN S PEER, NPI 1962693150, CMS profile ID 89459, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 182 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1962693150?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

182 matching records · $3,068.27 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 182 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 182.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $14.5009/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834327479 CMS
E.R. Squibb & Sons, L.L.C. $12.9309/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783559789 CMS
Horizon Therapeutics plc $6.5409/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797184991 CMS
Janssen Biotech, Inc. $10.2309/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788870743 CMS
Amgen Inc. $22.5009/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825109729 CMS
UCB, Inc. $22.6809/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807419909 CMS
AstraZeneca Pharmaceuticals LP $14.5809/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834350645 CMS
AbbVie Inc. $26.0209/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795584347 CMS
UCB, Inc. $21.2509/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807332439 CMS
AstraZeneca Pharmaceuticals LP $88.2209/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834335695 CMS
Mallinckrodt Hospital Products Inc. $14.6609/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845373835 CMS
GlaxoSmithKline, LLC. $18.4308/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802908597 CMS
Horizon Therapeutics plc $9.1408/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797184989 CMS
PFIZER INC. $17.1608/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832763781 CMS
Amgen Inc. $26.1508/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825109725 CMS
Janssen Biotech, Inc. $1.2508/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788870761 CMS
Janssen Biotech, Inc. $16.7908/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788870763 CMS
Amgen Inc. $16.9208/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825109689 CMS
UCB, Inc. $17.0208/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807395533 CMS
AbbVie Inc. $13.7908/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795584341 CMS
AstraZeneca Pharmaceuticals LP $13.9608/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834344841 CMS
AbbVie Inc. $26.0808/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795584335 CMS
Janssen Biotech, Inc. $14.7708/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788870757 CMS
E.R. Squibb & Sons, L.L.C. $14.6008/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783559781 CMS
Novartis Pharmaceuticals Corporation $14.2408/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813156405 CMS
UCB, Inc. $16.0808/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807381169 CMS
AbbVie Inc. $26.2408/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795584329 CMS
PFIZER INC. $22.3908/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832813313 CMS
PFIZER INC. $15.4808/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832790715 CMS
GlaxoSmithKline, LLC. $19.0707/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803100081 CMS
Novartis Pharmaceuticals Corporation $17.0007/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813156401 CMS
Janssen Biotech, Inc. $22.1807/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788870741 CMS
AbbVie Inc. $20.1507/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795584323 CMS
Horizon Therapeutics plc $20.0007/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797184987 CMS
Amgen Inc. $22.7807/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825109721 CMS
AstraZeneca Pharmaceuticals LP $11.0407/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834342455 CMS
AbbVie Inc. $22.3107/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795584317 CMS
Janssen Biotech, Inc. $15.6007/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788870771 CMS
Horizon Therapeutics plc $2.7907/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797184985 CMS
UCB, Inc. $28.9407/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807380465 CMS
E.R. Squibb & Sons, L.L.C. $0.9607/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783559769 CMS
E.R. Squibb & Sons, L.L.C. $17.1207/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783559773 CMS
AbbVie Inc. $12.0307/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795584311 CMS
AstraZeneca Pharmaceuticals LP $14.9206/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834321881 CMS
Amgen Inc. $22.9806/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825109717 CMS
Horizon Therapeutics plc $3.4106/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797184983 CMS
AbbVie Inc. $15.5706/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795584305 CMS
AbbVie Inc. $24.8206/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795584297 CMS
Horizon Therapeutics plc $9.6306/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797184981 CMS
Novartis Pharmaceuticals Corporation $12.5406/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813156397 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $12,018.72 221
PY2020 $2,260.10 144
PY2021 $3,068.27 182
PY2022 $3,899.30 170
PY2023 $10,120.96 238
PY2024 $4,389.44 184
PY2025 $13,556.87 217

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $189,272.33 44

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

44 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $9,983.23 12/17/2025 Non-covered Recipient Entity
INTROSCIENCE RESEARCH LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223289788
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,288.60 12/01/2025 Non-covered Recipient Entity
INTROSCIENCE RESEARCH LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223288873
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $21,764.35 11/21/2025 Non-covered Recipient Entity
INTROSCIENCE RESEARCH LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223288657
Principal investigator 1 ARGENX US, INC. $2,816.00 10/22/2025 Non-covered Recipient Entity
Introscience Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237151203
Principal investigator 1 ARGENX US, INC. $2,600.00 10/22/2025 Non-covered Recipient Entity
Introscience Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237151207
Principal investigator 1 ARGENX US, INC. $600.00 10/22/2025 Non-covered Recipient Entity
Introscience Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237151211
Principal investigator 1 ARGENX US, INC. $3,000.00 10/22/2025 Non-covered Recipient Entity
Introscience Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237151215
Principal investigator 1 ARGENX US, INC. $2,000.00 10/22/2025 Non-covered Recipient Entity
Introscience Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237151220
Principal investigator 1 ARGENX US, INC. $1,500.00 10/22/2025 Non-covered Recipient Entity
Introscience Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237151222
Principal investigator 1 ARGENX US, INC. $16,500.00 10/22/2025 Non-covered Recipient Entity
Introscience Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237151226
Principal investigator 1 ARGENX US, INC. $2,350.00 10/22/2025 Non-covered Recipient Entity
Introscience Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237151229
Principal investigator 1 ARGENX US, INC. $2,350.00 10/22/2025 Non-covered Recipient Entity
Introscience Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237151232
Principal investigator 1 ARGENX US, INC. $250.00 10/22/2025 Non-covered Recipient Entity
Introscience Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237151241
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $13,763.67 10/22/2025 Non-covered Recipient Entity
INTROSCIENCE RESEARCH LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223287161
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,252.87 10/03/2025 Non-covered Recipient Entity
INTROSCIENCE RESEARCH LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223286309
Principal investigator 1 ARGENX US, INC. $350.00 10/02/2025 Non-covered Recipient Entity
Introscience Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237151238
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,288.60 09/03/2025 Non-covered Recipient Entity
INTROSCIENCE RESEARCH LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223284925
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,614.32 08/27/2025 Non-covered Recipient Entity
INTROSCIENCE RESEARCH LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223284629
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $406.00 08/01/2025 Non-covered Recipient Entity
INTROSCIENCE RESEARCH LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223283559
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $15,940.00 08/01/2025 Non-covered Recipient Entity
INTROSCIENCE RESEARCH LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223283627
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,720.00 08/01/2025 Non-covered Recipient Entity
INTROSCIENCE RESEARCH LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223283629
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,000.00 08/01/2025 Non-covered Recipient Entity
INTROSCIENCE RESEARCH LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223283631
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,000.00 08/01/2025 Non-covered Recipient Entity
INTROSCIENCE RESEARCH LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223283633
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $25,357.38 07/23/2025 Non-covered Recipient Entity
INTROSCIENCE RESEARCH LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223282962
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,288.60 07/23/2025 Non-covered Recipient Entity
INTROSCIENCE RESEARCH LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223282964
Principal investigator 1 ARGENX US, INC. $2.10 07/01/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155551
Principal investigator 1 ARGENX US, INC. $37.60 07/01/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155555
Principal investigator 1 ARGENX US, INC. $39.75 07/01/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155558
Principal investigator 1 ARGENX US, INC. $286.50 07/01/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155563
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,977.76 06/25/2025 Non-covered Recipient Entity
INTROSCIENCE RESEARCH LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223281874
Principal investigator 1 ARGENX US, INC. $132.50 06/18/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155325
Principal investigator 1 ARGENX US, INC. $71.60 06/18/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155330
Principal investigator 1 ARGENX US, INC. $477.50 06/18/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155334
Principal investigator 1 ARGENX US, INC. $286.50 06/18/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155339
Principal investigator 1 ARGENX US, INC. $5.60 06/18/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155342
Principal investigator 1 ARGENX US, INC. $517.50 06/18/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155347
Principal investigator 1 ARGENX US, INC. $75.20 06/18/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155352
Principal investigator 1 ARGENX US, INC. $26.50 06/18/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155356
Principal investigator 1 ARGENX US, INC. $64.05 06/18/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155360
Principal investigator 1 ARGENX US, INC. $2.10 06/18/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155365
Principal investigator 1 ARGENX US, INC. $258.00 06/18/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155368
Principal investigator 1 ARGENX US, INC. $42.70 06/18/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155371
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,985.25 06/06/2025 Non-covered Recipient Entity
INTROSCIENCE RESEARCH LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223280886
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $15,000.00 04/01/2025 Non-covered Recipient Entity
INTROSCIENCE RESEARCH LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223277290